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use#LAATwo cases of multidrug-resistant tuberculosis (MDR 
TB) in a household are assumed to reﬂ  ect within-household 
transmission. However, in high-incidence areas of MDR 
TB, secondary cases may arise through exposure to 
MDR TB in the community. To estimate the frequency of 
multiple introductions of MDR TB into households, we 
used spoligotyping and 24-loci mycobacterial interspersed 
repetitive unit–variable number tandem repeats to classify 
isolates from 101 households in Lima, Peru, in which >1 
MDR TB patient received treatment during 1996–2004. We 
found different MDR TB strains in >10% of households. 
Alternate approaches for classifying matching strains 
produced estimates of multiple introductions in <38% of 
households. At least 4% of MDR TB patients were reinfected 
by a second strain of MDR Mycobacterium tuberculosis. 
These ﬁ  ndings suggest that community exposure to MDR 
TB in Lima occurs frequently. Rapid drug sensitivity testing 
of strains from household contacts of known MDR TB 
patients is needed to identify optimal treatment regimens.
T
he discovery and use of discriminating genetic 
markers such as IS6110 restriction fragment length 
polymorphisms (RFLPs), spacer oligonucleotides 
(spoligotyping), and mycobacterial interspersed repetitive 
unit–variable number tandem repeats (MIRU-VNTRs) 
(1) have improved our understanding of the transmission 
dynamics of tuberculosis (TB) (2,3). Genotyping studies, in 
which strains with matching sets of markers are considered 
potential members of a single transmission chain, have 
demonstrated that recent transmission plays a major role, 
even in low-incidence settings (4,5); that persons with 
recurrent episodes of TB may be having reinfection rather 
than relapse (6–8); that persons may be infected by >1 
isolate of Mycobacterium tuberculosis at the same time 
(9–11); and that transmission may occur in casual social 
settings (12).
Molecular epidemiologic studies have also 
demonstrated that secondary cases among close associates 
of known case-patients are not always members of the 
same chain of transmission, i.e., that infection may have 
been acquired from independent sources (13). Molecular 
investigations of households of multiple TB patients 
showed that cohabitating TB patients may be infected with 
distinct isolates of M. tuberculosis (14–16). For example, 
in 2 suburbs of Cape Town, South Africa, which have TB 
notiﬁ  cation rates of ≈320 cases per 100,000 population, 
researchers found that less than half (46%) of secondary 
TB cases within households had a TB isolate that matched 
an isolate from another case within the household by RFLP 
(16). Overall, <1 (19%) in 5 new TB cases occurring in 
these communities was the result of within-household 
transmission.
Although studies have shown that household contacts 
with TB are likely to have acquired infection independently 
in high-incidence settings, there are no published estimates 
of the probability that 2 household members with multidrug-
resistant TB (MDR TB: resistance to at least isoniazid and 
rifampin) share a similar genotype and are members of the 
same transmission chain. Molecular epidemiologic data 
from households with >1 MDR TB case can help shed 
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light on the transmissibility of highly drug-resistant disease 
and also help guide public health policy. For example, 
international guidelines for the management of known 
contacts of MDR TB patients recommend an empirical 
drug regimen based either on the drug-resistance proﬁ  le 
of an isolate from the suspected index MDR TB case-
patient or on the most common drug-resistance pattern 
in the community while drug sensitivity tests are pending 
(17–19). A better understanding of the relative importance 
of intrahousehold or community transmission may help to 
inform the choice of empirical regimen.
Despite a decreasing overall incidence of TB in Peru 
of ≈3.7% per year since 1996, the incidence of MDR TB 
has increased by ≈4.5% over the same period (20). The 
increasing incidence of MDR TB in densely occupied urban 
communities of Lima, Peru, poses obvious challenges for 
TB control. We report a molecular epidemiologic study 
within households in Lima in which >1 person received a 
diagnosis of MDR TB. We used spoligotyping and 24-loci 
MIRU-VNTR typing (21,22) to identify households that 
have had >1 introduction of MDR TB, and we explored 
the association of household factors with these multiple 
introduction events.
Materials and Methods
Study Setting, Participants, and Data
The estimated incidence of TB in Lima, Peru, is >130 
cases/100,000 persons; this estimate masks substantial 
heterogeneity in the actual distribution of TB within this 
large metropolitan area where poor areas often experience 
several-fold higher local incidence of disease than higher-
income areas (23). For example, in 2000 in northern 
metropolitan Lima (population 3,186,199), the incidence 
of active TB was 232 cases/100,000 persons (24). A 
nationwide survey in 2006 reported that 5.3% of all new 
cases and 23.6% of retreatment cases were MDR TB 
(25). Since 1996, Partners in Health and Socios en Salud 
Sucursal Peru have worked with the Peru Ministry of Health 
to implement a program to treat patients with active MDR 
TB by using supervised, individualized, antimicrobial drug 
regimens delivered on an ambulatory basis (26–28).
We previously reported the TB incidence in a cohort 
of household contacts of the patients treated for MDR TB 
(29). A household was eligible for inclusion in the study if 
>2 members had been treated for MDR TB by this program 
during 1996–2004, and if >1 MDR M. tuberculosis isolate 
obtained from each person was available for analysis. 
All available (pretreatment and ongoing treatment) MDR 
isolates from patients in eligible households were included 
in this analysis. Demographic data, drug-susceptibility test 
results, and information about the physical condition of the 
household structure were abstracted from the electronic 
records of the MDR TB program. This study was reviewed 
and approved by the Committee on Human Studies of the 
Ofﬁ  ce of Research Subject Protection of Harvard Medical 
School.
Laboratory Methods and Drug-Susceptibility Testing
Drug-susceptibility testing and genotyping by using 
MIRU-VNTR and spoligotyping were performed by the 
Supranational Reference Laboratory at the University 
of Massachusetts Medical School. A standard agar plate 
proportion method was used for drug-susceptibility testing 
of M. tuberculosis isolates. The ﬁ  rst-line and second-line 
drugs tested were isoniazid (0.2 mg/L, 1.0 mg/L, and 
5.0 mg/L), rifampin (1.0 mg/L), streptomycin (2.0 mg/L 
and 10.0 mg/L), ethambutol (5.0 mg/L), kanamycin (5.0 
mg/L), ethionamide (10.0 mg/L), capreomycin (10.0 
mg/L), oﬂ  oxacin (2.0 mg/L), and p-amino salicylic acid 
(8.0 mg/L). Susceptibility to pyrazinamide (100 mg/L) was 
determined by using the BACTEC 460 Liquid Medium 
System (Becton Dickinson, Sparks, MD, USA). We only 
included drugs to which resistance had been tested for 
>70% of isolates in the study.
MIRU-VNTR Genotyping
DNA for PCR analysis was prepared by using a 
simple thermolysis procedure. PCR ampliﬁ  cation of the 
24 MIRU-VNTR loci was conducted as described (22,30) 
with minor modiﬁ  cations. The PCR mixture contained 2 
μL of thermolysate, 1× PCR buffer, 1 mol/L betaine, 0.5 
U Taq DNA polymerase (Takara Bio, Madison, WI, USA), 
200 μmol/L of each dNTP, and 0.3 μmol/L of each ﬂ  anking 
primer.
An ABI Thermal Cycler 2720 (Applied Biosystems, 
Foster City, CA, USA) was used for PCRs. Initial 
denaturation at 94°C for 5 min was followed by 35 cycles 
of denaturation at 94°C for 30 s, annealing at 62°C for 30 s, 
and elongation at 70°C for 45 s; and a ﬁ  nal extension step at 
72°C for 10 min. M. tuberculosis H37RV DNA and sterile 
distilled water were included in each test run as positive 
and negative controls, respectively.
PCR products were analyzed in 2 ways. First, DNA 
fragments from ampliﬁ   cation with primers speciﬁ  c  for 
loci ETRA, ETRB, ETRC, ETRD, MIRU2, MIRU20, 
MIRU23, MIRU24, MIRU26, Mtub21, Mtub29, Mtub30, 
Mtub34, and Qub11b were separated by using standard 2% 
agarose gel electrophoresis. Second, DNA fragments from 
ampliﬁ  cation with primers speciﬁ  c for loci ETRE, MIRU10, 
MIRU16, MIRU27, MIRU39, MIRU40, Mtub04, Mtub39, 
Qub26, and Qub4156 were analyzed by electrophoresis 
with the QIAxcel System and the QIAxcel DNA Screening 
Kit (both from QIAGEN, Valencia, CA, USA).
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Mycobacterial DNA was prepared by using the same 
thermolysis protocol as for MIRU-VNTR typing. For DNA 
ampliﬁ  cation, 0.15 μL Tth polymerase (5 U/μL; Roche, 
Pleasanton, CA, USA) was added to 50 μL of PCR mixture, 
and the following ampliﬁ  cation proﬁ  le was used: 3 min at 
96°C; 35 cycles for 1 min at 96°C, 1 min at 55°C, and 30 s 
at 72°C; and 5 min at 72°C.
Spacer oligonucleotide typing was performed by 
using the Multianalyte Proﬁ   ling System (Luminex 
Inc., Austin, TX, USA). The procedure was conducted 
according to the protocol reported by Cowan et al. (31) 
with adaptations for a 96-well format. Fluorescence signals 
indicating hybridization strength were analyzed by using 
Bio-Plex Suspension Array System Instrument Luminex 
100xMAP Technology (Luminex Molecular Diagnostics 
Inc., Toronto, Ontario, Canada) and the Bio-Rad BioPlex 
Manager Program version 4.1.1 (Bio-Rad Laboratories, 
Hercules, CA, USA). Lineage and the shared type for each 
isolate were assigned based on matching the spoligotype 
patterns with those listed in the SpolDB4 database (32).
Identiﬁ  cation of Multiple Introductions of 
M. tuberculosis into a Household
Households were classiﬁ   ed as having evidence of 
repeated introduction of TB from the community if isolates 
from >2 patients with MDR TB within 1 household had 
different molecular genotypes. Supply et al. proposed a 
standard approach for characterizing the relatedness of M. 
tuberculosis isolates by spoligotyping and 24-loci MIRU-
VNTR. They found that the combination of these methods 
(which requires including >15 of the most diverse loci for 
MIRU-VNTR analysis) has comparable discriminatory 
power to IS6110 RFLP typing (22). We present minimum 
and maximum estimates of the proportion of households 
judged to have evidence of multiple TB introductions on 
the basis of spoligotyping and MIRU-VNTR genotyping 
data.
We also examined a classiﬁ  cation approach recently 
used by Narayanan et al. (7). Nonmatching strains are 
deﬁ  ned as those strains with >1 spoligotype spacer or >1 
MIRU-VNTR locus difference. Enabling different degrees 
of stringency in calling 2 (or more) strains a match reﬂ  ects 
our underlying uncertainty about how rapidly spoligotypes 
and MIRU-VNTR genotypes change because of mutations 
at marker loci during the natural history of disease and 
through chains of transmission that may span decades.
Identiﬁ  cation of Reinfection Events
We genotyped all available MDR isolates of patients 
within study households. Among participants from 
whom >2 isolates were available, we identiﬁ  ed episodes 
of reinfection on the basis of differences in genotypes. 
We used a similar approach for comparing genotypes for 
identifying episodes of reinfection and repeated household 
introduction.
Statistical Analysis
SAS version 9.2 (SAS, Cary, NC, USA) was used for 
statistical analysis. We performed standard nonparametric 
tests for assessing univariate associations between 
household-level factors and the probability of repeated 
introduction.
Results
We identiﬁ  ed 105 households in which >1 MDR M. 
tuberculosis isolate was available from each of >2 different 
household members. In total, 391 MDR isolates from 236 
persons were available for molecular typing. Spoligotyping 
and MIRU-VNTR analyses were successfully completed 
on samples from >2 participants from 101 (96%) of these 
households. These analyses resulted in a set of 384 (98%) 
isolates from 232 (98%) persons. Characteristics of persons 
and households included in the study are shown in Table 
1. There were an additional 142 households for which 
we knew of >2 patients with MDR TB, but for whom 
M. tuberculosis specimens were no longer available for 
genetic analysis. No statistically signiﬁ  cant differences in 
size, density, or age distribution of members were found 
between the households that were included and those not 
included in this study.
Of 384 isolates, 228 (59%) were tested for sus-
ceptibility to a sufﬁ  cient number of second-line drugs to 
identify extensively drug-resistant M. tuberculosis strains 
(MDR plus additional resistance to a ﬂ  uoroquinolone 
and a second-line, injectable antimicrobial drug [either 
kanamycin, amikacin, or capreomycin]). Thirty-one (14%) 
of these 228 isolates were conﬁ  rmed as extensively drug 
resistant and were obtained from 15 patients, none of whom 
were living in the same household.
Multiple Introductions of MDR M. tuberculosis 
into Households
Using a permissive deﬁ  nition of matching in which we 
included strains that differed by 1 spoligotype spacer to be 
matched, we estimated that 10 (10%) of households had 
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Table 1. Characteristics of 101 households with MDR TB, Lima, 
Peru, 1996–2004* 
Characteristic Median (IQR) 
Persons per household  8 (6–10) 
Persons per bedroom  2.5 (1.75–4.33) 
Participants per household  2 (2–2) 
Participants, n = 232 
 Age,  y  23.8  (19.2–30.5) 
  Male sex, %  57.2
*MDR TB, multidrug-resistant tuberculosis; IQR, interquartile range. RESEARCH
distinct MDR isolates and showed evidence of repeated 
introduction. The strictest deﬁ  nition of matching, which 
required exact matches in spoligotype and at all 24-loci 
of the MIRU-VNTR analysis, showed that 38 (38%) of 
households had evidence of repeat introduction of MDR 
TB from the community (Figure). Using the approach of 
Narayanan et al. (7) for identifying nonmatching strains 
(pairs with >1 spoligotype spacer or 1 MIRU-VNTR locus 
difference), we classiﬁ  ed 16 (16%) households as settings 
with multiple introductions of MDR TB.
The 16 households in which >2 persons had an 
MDR M. tuberculosis isolate that was different from that 
obtained from another person in the household, according 
to the deﬁ  nition of Narayanan et al. (7), are shown in online 
Appendix Table 1 (www.cdc.gov/EID/content/17/6/969-
appT1.htm). Seven of these households also had evidence 
of within-household transmission of MDR TB. Closer 
inspection of spoligotypes isolated from these households 
indicated that 6 of the 16 households, although failing 
to meet the proposed criterion for matching, had similar 
isolates (households 112, 192, 557, 960, 263, and 645). 
If these 6 households are classiﬁ  ed as having evidence 
of within-household transmission, our best estimate of 
the number of households with evidence of multiple 
introductions of MDR strains is reduced to 10 (10%). 
Under these criteria, the percentage of households with 
only evidence of probable within-household transmission 
is 90%.
We used the 10 households as our most conservative 
set of households with evidence of multiple introductions 
of MDR stains and searched for household factors that 
were associated with multiple introduction events. We did 
not ﬁ  nd any signiﬁ  cant associations; speciﬁ  cally, the size 
and density of households, the quality of the household 
structure, and time span over which isolates were accrued 
from households all appeared to be unrelated to multiple 
introductions (Table 2). In addition, no signiﬁ  cant difference 
was found in the number of drugs to which the isolate from 
the ﬁ  rst patient was resistant between households that had 
repeated introduction (mean 5.1 drugs) and households that 
had evidence of probable within-household transmission 
(mean 5.3 drugs; p = 0.75).
Evidence of MDR Reinfection
Ninety persons had >1 MDR TB isolate available 
for analysis. Using the deﬁ   nition of matching strains 
of Narayanan et al. (7), we found that 5 (6%) of these 
persons had 2 distinct strains of MDR M.  tuberculosis 
during the period of follow-up and the remaining 85 (94%) 
showed repeated isolation of the same MDR strain (online 
Appendix Table 2, www.cdc.gov/EID/content/17/6/969-
appT2.htm). Closer inspection of the isolates available from 
these 5 persons showed that 1 person (a 20-year-old man) 
from household 977 may not have been reinfected. Three 
isolates were available from this person. The ﬁ  rst isolate 
had a slightly different spoligotype than the 2 isolates 
subsequently obtained, but the MIRU-VNTR pattern was 
the same for all 3 isolates.
Discussion
In the absence of molecular epidemiologic data, 
secondary cases of MDR TB within a household are 
generally assumed to be the result of within-household 
transmission. In an area with increasing incidence of MDR 
TB (20), we found that 90% of household contacts of MDR 
TB index cases with active disease and drug-susceptibility 
test results had MDR TB (29). Our present study, in a 
subset of that cohort, used genotyping on the basis of 
spoligotyping and 24-loci MIRU-VNTR, which has been 
shown in other settings to have comparable discriminatory 
power to IS6110 RFLP (21). Our study shows that there 
was at least a 10% risk that a subsequent case of MDR TB 
occurring within the home of a known MDR TB patient 
was the result of transmission in the community rather than 
transmission in the household. This estimate represents 
a lower boundary of the contribution of community 
transmission to the appearance of secondary MDR cases 
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Figure. Numbers of households classiﬁ   ed as having multiple 
multidrug-resistant (MDR) tuberculosis introductions by 6 
deﬁ  nitions of matching genotypes, Lima, Peru, 1996–2004. MIRU-
VNTR, mycobacterial interspersed repetitive unit–variable number 
tandem repeat.Multiple Introductions of MDR TB into Households
within a home because matching strains within a household 
(which we would categorize as within-home transmission) 
may be caused by transmission from other sources in 
the community. Because circulating MDR strains were 
heterogeneous (Table 3), the magnitude of this bias may 
not be substantial.
We did not ﬁ  nd any easily measured household factors 
associated with risk for repeated introductions compared 
with within-home transmission. We had hypothesized that 
a high household density (persons/bedroom) or low quality 
of household structure may be associated with a higher 
probability of within-home transmission, conditional upon 
observing multiple cases within a home, but this hypothesis 
was not supported by these data. This ﬁ  nding  may 
reﬂ  ect an absence of this association between household 
characteristics and risk for within-home transmission or, 
alternatively, it may reﬂ  ect the relatively small number 
of repeated introduction events that we observed and our 
limited power to test such associations. Accordingly, 
although our observations provide convincing evidence 
that repeated introduction of MDR TB into households 
occurs in these settings, further studies are needed to 
determine whether household factors, number of persons 
within these households, or strains present within these 
households are associated with an increased risk for within-
home transmission or repeated exposure in the community.
Genetic (33) or acquired susceptibility (34) to infection 
and disease may play a role in the accumulation of multiple 
TB cases within households. Because household members 
are likely to share genetic or environmental risk factors, 
or both, persons living with TB case-patients may be 
particularly likely to be infected and acquire disease 
whether they are infected by their household contact or in 
the community.
Our ﬁ  ndings provide evidence to support international 
guidelines for management of active TB among contacts 
of known MDR TB cases (17–19) because they conﬁ  rm 
that among strains from persons for which genotyping test 
results are available, <90% of household contacts with 
MDR TB were infected with the same strain as the index 
patient. Our ﬁ  ndings also highlight limitations associated 
with such policies. Because subsequent cases of MDR TB 
in a household may be caused by community transmission, 
policies that specify that apparent secondary case-patients 
receive therapy on the basis of the drug-susceptibility 
proﬁ  le of an isolate from the initial MDR TB patient may 
result either in effective drugs being needlessly withheld 
or in administration of drugs to which the strain is already 
resistant. This policy may result in acquisition of additional 
resistance to second-line drugs and prolonged opportunity 
for transmission of highly drug-resistant strains within 
homes and in the community (35,36).
These  ﬁ   ndings support the use of rapid drug-
resistance tests to determine drug susceptibility proﬁ  les 
in known contacts of MDR TB patients. Molecular tests 
for resistance, such as line probe assays and cartridge-
based PCRs (i.e., GeneXpert; Cepheid, Sunnyvale, CA, 
USA), are promising and have been endorsed by the 
World Health Organization for determining resistance to 
ﬁ  rst-line drugs (37). However, although new diagnostic 
tests in development also detect resistance to second-line 
drugs (38,39), these tests have not yet been optimized for 
use in guiding clinical care. New rapid phenotypic tests 
for resistance, such as the microscopic-observation drug-
susceptibility assay, have also not yet been adequately 
tested under ﬁ  eld conditions for their capacity to be used 
in selection of tailored regimens for MDR TB (40). Known 
contacts of MDR TB patients should be a high-priority, 
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Table 2. Association between household factors and repeated introduction of MDR TB, Lima, Peru, 1996–2004* 
Factor  Introduction, n = 10†  No introduction, n = 91  p value 
No. persons  7.5 (6–8)  8 (7–11)  0.18
Persons per bedroom  2.6 (1.7–2.7)  2.4 (1.75–5)  0.43
Homes of substandard quality‡  1/9 (11)  23/64 (36)  0.44
Mean age of household members, y   28 (23–32)  26 (21–30)  0.39
Duration between first and last isolate obtained from household, d  389 (167–724)  345 (204–599)  0.92
*Values are median (interquartile range) or no. positive/no. tested (%). MDR TB, multidrug-resistant tuberculosis. 
†Households classified as having repeated MDR TB introductions for these analyses are indicated in online Appendix Table 1 
(www.cdc.gov/EID/content/17/6/969-appT1.htm). 
‡Substandard housing was defined as a dwelling with a dirt floor; walls made of straw matting, plastic, or plywood; a roof made of straw matting, plastic, or 
plywood; or no access to water in the home (data were not available for all households). 
Table 3. Strain lineages of Mycobacterium tuberculosis detected 
in the study population, Lima, Peru, 1996–2004 
Lineage No. (%) 
Beijing 19 (4.9) 
H1 22 (5.7) 
H3 22 (5.7) 
LAM1 25 (6.5) 
LAM3 12 (3.1) 
LAM4 6 (1.6) 
LAM5 47 (12.2) 
LAM9 38 (9.9) 
T1 85 (22.1) 
T2 19 (4.9) 
T5_MAD2 2 (0.5) 
U1 ( 0 . 3 )  
X3 17 (4.4) 
No match  69 (18.0) RESEARCH
high-yield study population for assessing the immediate 
utility of these new tools.
A limitation of our study is that we cannot deﬁ  nitively 
distinguish the 2 mechanisms by which distinct MDR 
isolates may appear within households. First, household 
members may have been infected by different drug-
susceptible strains in the community and acquired drug 
resistance through deﬁ   cient drug treatment. Second, 
household members may have been directly infected by 
different MDR strains in the community. Distinguishing 
between these 2 possibilities is essential because each would 
cause a distinct public health response. The ﬁ  rst mechanism 
suggests that detailed investigation of individual-level or 
household-level risk factors for acquisition of MDR TB 
was needed and would indicate a need for greater treatment 
support and supervision for patients with drug-susceptible 
disease. The second mechanism indicates a need to improve 
infection control in the community or to facilitate diagnosis 
and effective treatment for persons with MDR TB to reduce 
the duration of infectiousness. In most circumstances, we 
expect acquisition and transmission to contribute to the 
appearance of multiple cases of MDR TB within homes, 
and efforts to reduce the incidence of drug-resistant disease 
will need to address these factors.
Although we have insufﬁ  cient data for previous TB 
episodes and treatment for persons in our study to exclude 
possible independent acquisition of MDR TB among 
household members because of inadequate treatment, our 
ﬁ  nding that >4 persons showed evidence of reinfection by 
a second (i.e., different) MDR TB strain provides evidence 
that there is a high risk for MDR TB exposure in this 
community. HIV status was known for only ≈50% of the 
persons in the study. Among those tested, only 3 (3%) of 
102 were HIV infected and none of the 3 HIV-infected 
persons were among persons in households in which 
multiple introductions of MDR TB were detected. If co-
infection with HIV was common, it would be expected to 
increase the probability of rapid progression to disease and 
lead to higher risks of multiple cases of unlinked disease 
within households. Because HIV co-infection was so rare, 
it is unlikely that this explains the study results.
Our results extend ﬁ   ndings from previous studies 
showing that a substantial fraction of cohabiting persons 
have independently acquired TB in the community 
(13–16). In contrast to earlier studies that compared 
relative contributions of within-home and community 
transmission, all persons in our study had MDR TB. We 
found that although 90% of households had evidence of 
intrahousehold transmission, 10% had >2 independent 
introductions of MDR M. tuberculosis strains from 
the community. This ﬁ   nding suggests that the risk for 
community or extrahousehold transmission of MDR TB in 
Lima is high. Furthermore, it indicates that known MDR 
TB contacts initiating empirical treatment for MDR TB 
treatment require access to drug susceptibility testing to 
ensure that they receive the drugs to which their isolate 
is susceptible. National TB programs should be wary of 
applying empirical regimens on the basis of population-
level drug susceptibility data without better understanding 
of the relative role of intrahousehold and community 
transmission of MDR TB.
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